To help labs get the answers they so desperately need, The Dark Intelligence Group has launched the COVID-19 STAT Intelligence Briefings Service.
During this disruptive SARS-CoV-2 pandemic, TDIG has created this free intelligence service with a total focus on COVID-19 and everything labs need to meet the business challenges of the pandemic, including the latest on rapid molecular serology COVID-19 testing, with sources and supply chain updates; How labs are getting paid for COVID-19 by Medicare, Medicaid, and private health plans; and Daily updates on changes to federal regulations and directives from the FDA, CDC, and CMS.
COVID-19 STAT Intelligence Briefings service updates daily. It includes briefings, interviews with leading subject matter experts, podcasts and webinars, plus timely analysis of the daily changes in the pandemic.
It is all actionable information, supplemented with real-time national lab test dashboards fed with data from TDIG partners at XIFIN, Visiun, and hc1.com.
COVID-19 STAT Intelligence Briefings is also introducing twice-weekly conference calls, so attendees can hear updates from nationally known thought leaders and get critical questions answered on managing their laboratories during the SARS-CoV-2 outbreak.
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder
CSL Vifor and Travere Therapeutics gain full EU approval for FILSPARI in IgA nephropathy
LogiCare3PL supporting Soleno Therapeutics' commercial launch of VYKAT XR
argenx receives positive CHMP opinion for VYVGART subcutaneous injection in CIDP treatment
Camurus' Oczyesa recommended for European regulatory approval for acromegaly treatment
Life Molecular Imaging's Neuraceq available at PharmaLogic Salt Lake City
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
Coologics' seed funding round raises over USD3m
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older